ARTICLE | Clinical News

Fluzone QIV regulatory update

February 2, 2015 8:00 AM UTC

FDA approved an sBLA from Sanofi for Fluzone Intradermal Quadrivalent to vaccinate against influenza disease caused by influenza A subtype viruses and type B viruses in subjects ages 18-64. Sanofi will launch the vaccine in the U.S. for the 2015-16 flu season. The intradermal inactivated quadrivalent influenza vaccine contains 2 strains of influenza type A (H1N1 and H3N2) and 2 strains of influenza type B (Yamagata and Victoria lineages). ...